Endonovo Therapeutics Inc ENDV-GB:OTCPK

*Data is delayed | Exchange | USD
Last | 1:27 PM EDT
0.0025UNCH (UNCH)
Volume
390,599
52 week range
0.00 - 0.02
Loading...
  • Open0.0028
  • Day High0.0028
  • Day Low0.0024
  • Prev Close0.0025
  • 52 Week High0.02
  • 52 Week High Date05/05/23
  • 52 Week Low0.00
  • 52 Week Low Date02/07/24

Key Stats

  • Market Cap796,878.934
  • Shares Out318.75M
  • 10 Day Average Volume155,700.14
  • Dividend-
  • Dividend Yield-
  • Beta-0.31
  • YTD % Change-71.26

KEY STATS

  • Open0.0028
  • Day High0.0028
  • Day Low0.0024
  • Prev Close0.0025
  • 52 Week High0.02
  • 52 Week High Date05/05/23
  • 52 Week Low0.00
  • 52 Week Low Date02/07/24
  • Market Cap796,878.934
  • Shares Out318.75M
  • 10 Day Average Volume155,700.14
  • Dividend-
  • Dividend Yield-
  • Beta-0.31
  • YTD % Change-71.26

RATIOS/PROFITABILITY

  • EPS (TTM)-0.07
  • P/E (TTM)-0.04
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-1.97M
  • ROE (TTM)-
  • Revenue (TTM)255,719.99
  • Gross Margin (TTM)96.21%
  • Net Margin (TTM)-1,722.26%
  • Debt To Equity (MRQ)-30.74%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Endonovo Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and...
Alan Collier
Chief Executive Officer, Interim Chief Financial Officer, Secretary, Director
Ira Weisberg
President, Chief Commercial Officer - Medical Division
Address
6320 Canoga Avenue, 15Th Floor
Woodland Hills, CA
91367
United States